Stock APGE APOGEE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Apogee Therapeutics, Inc.

Equities

APGE

US03770N1019

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-24 EDT 		5-day change 1st Jan Change
48.03 USD +4.32% Intraday chart for Apogee Therapeutics, Inc. -4.53% +71.90%
05-15 Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases CI
05-13 Apogee Therapeutics' Q1 Net Loss Widens MT

Evolution of the average Target Price on Apogee Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

f33a33d7c887bb36f0e704f081477e.PY595WXqhu42A97iGBjuK-CGk6x4Bv2AJUJM3b3SQLA.TN4rjwrY1J4GZrqGLHaCfJrAwsUKTKr6Fho1ufbiOtdkvQfWUKPM33R6lw~ec2f770e70d6d8032d987bd74c71cc0d

Analyst Recommendations on Apogee Therapeutics, Inc.

BofA Securities Starts Coverage on Apogee Therapeutics With Buy Rating, $80 Price Target MT
Jefferies Adjusts Price Target on Apogee Therapeutics to $75 From $37, Maintains Buy Rating MT
Wedbush Raises Apogee Therapeutics' PT to $87 From $40 After Reporting Initial Safety, PK Results From Phase 1 Trial of APG777; Maintains Outperform Rating MT
Guggenheim Adjusts Apogee Therapeutics' Price Target to $44 From $29, Maintains Buy Rating MT
BTIG Initiates Apogee Therapeutics With Buy Rating, Price Target is $43 MT
TD Cowen Initiates Apogee Therapeutics With Outperform Rating MT
Stifel Initiates Apogee Therapeutics With Buy Rating, $34 Price Target MT
Jefferies Initiates Apogee Therapeutics With Buy Rating, $29 Price Target MT
Guggenheim Starts Apogee Therapeutics With Buy Rating, $29 Price Target MT
Wedbush Initiates Apogee Therapeutics at Outperform With $40 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
48.03 USD
Average target price
84.83 USD
Spread / Average Target
+76.63%
High Price Target
95 USD
Spread / Highest target
+97.79%
Low Price Target
75 USD
Spread / Lowest Target
+56.15%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Apogee Therapeutics, Inc.

BofA Securities
Jefferies & Co.
Wedbush
Guggenheim
BTIG
TD Cowen
Stifel Nicolaus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. APGE Stock
  4. Consensus Apogee Therapeutics, Inc.